Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

RCT (n=256) found that brensocatib increased the time to first exacerbation vs placebo (25th percentile time to exacerbation = 67 days for placebo, 134 days for 10 mg and 96 days for 25 mg, HR 0.58, 95%CI 0.35-0.95 for 10 mg vs placebo, and 0.62, 0.38-0.99 for 25 mg vs placebo).

New England Journal of Medicine